ACE2 and hypertensive disorder: This raised the argument whether it is safe to use ACEi/ARBs to manage hypertension in patients with COVID-19, considering that higher expression of ACE2 leads to increased availability of the binding sites for the SARS-CoV-2 entry into cells (Rico-Mesa et al., 2020).